Vir Biotechnology (VIR) Enterprise Value (2018 - 2026)

Vir Biotechnology has disclosed Enterprise Value across 9 years of filings, most recently posting -$470.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$470.4 million, down 65.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$470.4 million (down 65.48% YoY), and the FY2025 annual result was -$460.9 million, up 39.94% from the prior year.
• Enterprise Value came in at -$470.4 million for Q1 2026 at Vir Biotechnology, down from -$460.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$95.1 million in Q3 2024 to a low of -$2.4 billion in Q4 2022.
• The 5-year median for Enterprise Value is -$767.4 million (2024), against an average of -$937.8 million.
• Across the five-year window, Enterprise Value tumbled 949.78% in 2022 and soared 92.37% in 2024, its largest moves.
• Vir Biotechnology's Enterprise Value stood at -$2.4 billion in 2022, then jumped by 89.39% to -$251.4 million in 2023, then tumbled by 205.23% to -$767.4 million in 2024, then soared by 39.94% to -$460.9 million in 2025, then dropped by 2.06% to -$470.4 million in 2026.
• The last three Enterprise Value figures came in at -$470.4 million (Q1 2026), -$460.9 million (Q4 2025), and -$178.8 million (Q3 2025), per Business Quant data.